Skip to main content

Table 1 Patient’s characteristics

From: Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?

No. patients 102 (100)
Age (years): median value (range) 60 (33-85)
Previous adjuvant chemotherapy
 No 37 (36.3)
 Yes 39 (38.2)
 Unknown/Not available 26 (25.5)
Previous adjuvant endocrine therapy
 No 22 (21.6)
 Yes 54 (52.9)
 Unknown/Not available 26 (25.5)
Histotype
 Ductal 76 (74.5)
 Lobular 14 (13.7)
 Other 7 (6.9)
 Unknown 5 (4.9)
Tumor stage
 1 30 (29.4)
 2 42 (41.1)
 3 2 (2)
 4 12 (11.8)
 Unknown 16 (15.7)
Grade of primary tumor
 1 2 (2)
 2 34 (33.3)
 3 32 (31.4)
 Unknown 34 (33.3)
Nodal involvement
 0 24 (23.5)
 1 36 (35.3)
 2 11 (10.8)
 3 11 (10.8)
 Unknown 20 (19.6)
Metastases (at diagnosis)
 0 76 (74.5)
 1 26 (25.5)
Type of first-line endocrine therapy
 Letrozole 46 (45.1)
 Anastrozole 22 (21.6)
 Exemestane 26 (25.5)
 Tamoxifen 5 (4.9)
 Fulvestrant 3 (2.9)